A series of (1E,2E)-1-((2-chloroquinolin-3-yl)methylene)-2-hydrazine derivatives (6a-j) were synthesized by reacting 2-chloroquinoline-3-carbaldehyde (3a) with hydrazine hydrate to yield (E)-1-((2-chloroquinolin-3-yl)methylene)hydrazine (4) which upon reacting with substituted benzaldehyde 5(a-j) in methanol yield the title compounds at room temperature. The synthesized compounds were characterized by FTIR, 1H-13C NMR and mass spectral analysis. The synthesized compounds were tested for in-vitro antiproliferative activity against breast (MCF-7), leukemic (K562), cervical (HeLa), colorectal adreno (Colo205) and hepato cellular (HepG2) cancer cell lines by MTT assay. The in-silico ADMET studies of the molecules were analyzed for their drug likeliness and toxic properties. The antiproliferative study reveals that compounds 6a, 6d were found to be active against HeLa, K562 and HepG2 cell lines, respectively when compared with the drug doxorubicin. The ADMET studies of title compounds found to be obeying the Lipinski rule of five and are non-toxic. The possible hits generated from the screening could be taken as hits in the development of lead molecules in drug discovery of new antiproliferative/cytotoxic entities from quinoline.
Loading....